Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five years.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Pharmaceutical & Healthcare, Global, Deals Summary 13

2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2018 13

2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2018 by Quarter 15

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2018 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2018 18

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2018 19

2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2018 19

2.5.1 Takeda Pharma Acquires Shire 19

2.5.2 Cigna Acquires Express Scripts Holding Company for USD67 Billion 20

2.5.3 Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 20

2.5.4 GlaxoSmithKline Acquires Remaining

36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 21

2.5.5 Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 21

2.5.6 Celgene Acquires Juno Therapeutics for USD9 Billion 21

2.5.7 Novartis Acquires AveXis for USD8.7 Billion 22

2.5.8 Celgene Acquires Impact Biomedicines for up to USD7 Billion 23

2.5.9 Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 23

2.5.10 GlaxoSmithKline Acquires TESARO 23

3 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 25

3.1 Pharmaceuticals & Healthcare, Global, M&A, 2018 25

3.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2018 by Quarter 26

3.1.2 Top M&A Deals in 2018 27

3.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2018 28

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2018 29

3.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2018 by Quarter 30

3.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2018 31

3.2.3 Top IPOs in 2018 32

3.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2018 32

3.2.5 Top Secondary Offerings in 2018 33

3.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2018 34

3.2.7 Top PIPE Deals in 2018 35

3.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2018 35

3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2018 37

3.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2018 by Quarter 38

3.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2018 39

3.3.3 Top Public Debt Offerings in 2018 40

3.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2018 40

3.3.5 Top Private Debt Placements in 2018 41

3.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2018 42

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2018 43

3.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2018 by Quarter 44

3.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2018 46

3.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2018 47

3.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2018 48

3.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2018 49

3.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2018 50

3.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2018 51

3.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2018 52

3.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2018 53

3.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2018 53

3.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2018 54

3.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2018 by Quarter 55

3.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2018 56

3.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2018 57

3.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2018 58

3.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2018 59

3.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2018 60

3.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2018 61

3.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2018 62

3.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2018 63

3.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2018 63

3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2018 64

3.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2018 by Quarter 65

3.6.2 Top Private Equity Deals in 2018 66

3.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2018 66

3.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2018 68

3.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2018 by Quarter 69

3.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2018 70

3.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2018 71

3.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2018 72

3.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 73

3.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2018 73

3.7.7 Top Venture Financing Deals in 2018 75

4 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 76

4.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2018 76

4.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2018 by Quarter 77

4.1.2 Oncology – Deals of the Year 78

4.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2018 81

4.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2018 by Quarter 82

4.2.2 Central Nervous System – Deals of the Year 83

4.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2018 88

4.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2018 by Quarter 89

4.3.2 Infectious Disease – Deals of the Year 90

4.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2018 93

4.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2018 by Quarter 94

4.4.2 Immunology – Deals of the Year 95

4.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2018 98

4.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2018 by Quarter 99

4.5.2 Cardiovascular – Deals of the Year 100

4.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2018 105

4.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2018 by Quarter 106

4.6.2 Metabolic Disorders – Deals of the Year 107

4.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2018 110

4.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2018 by Quarter 111

4.7.2 Gastrointestinal – Deals of the Year 112

5 Pharmaceuticals & Healthcare, Deal Summary, By Geography 115

5.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2018 115

5.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2018 by Quarter 116

5.1.2 North America – Deals of the Year 117

5.2 Pharmaceuticals & Healthcare, European Region Deals, 2018 120

5.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2018 by Quarter 121

5.2.2 Europe – Deals of the Year 122

5.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2018 125

5.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2018 by Quarter 126

5.3.2 Asia-Pacific – Deals of the Year 127

5.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2018 130

5.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2018 by Quarter 131

5.4.2 Rest of the World – Deals of the Year 132

6 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 135

6.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2018 135

6.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2018 137

7 Further Information 138

7.1 Methodology 138

7.2 About GlobalData 139

7.3 Contact Us 139

7.4 Disclosure information 139

7.5 Disclaimer 140

List of Tables

1.1 List of Tables

Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 14

Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2018-Q4 2018 16

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2018 18

Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2018 19

Table 5: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 26

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 27

Table 7: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2018 27

Table 8: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2018 28

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 29

Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 30

Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 31

Table 12: Pharmaceuticals & Healthcare, Global, Top IPOs, 2018 32

Table 13: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 33

Table 14: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2018 33

Table 15: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 34

Table 16: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2018 35

Table 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2018 36

Table 18: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 37

Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 38

Table 20: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 39

Table 21: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2018 40

Table 22: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 41

Table 23: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2018 41

Table 24: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2018 42

Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2014 – 2018 43

Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2018–Q4 2018 44

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2018 46

Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2018 47

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2018 48

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2018 50

Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2018 52

Table 32: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2018 52

Table 33: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2018 53

Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2018 53

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 54

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018–Q4 2018 55

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2018 56

Table 38: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2018 57

Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2018 58

Table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015 – Q4 2018 60

Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2018 62

Table 42: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2018 62

Table 43: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2018 63

Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2018 63

Table 45: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 64

Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 65

Table 47: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2018 66

Table 48: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2018 67

Table 49: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 68

Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 69

Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2018 71

Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2018 72

Table 53: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2018 73

Table 54: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2018 74

Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2018 75

Table 56: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 77

Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 78

Table 58: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 82

Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 83

Table 60: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 89

Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 90

Table 62: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 94

Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 95

Table 64: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 99

Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 100

Table 66: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 106

Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 107

Table 68: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 111

Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 112

Table 70: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 116

Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2018–Q4 2018 117

Table 72: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 121

Table 73: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2018-Q4 2018 122

Table 74: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 126

Table 75: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2018-Q4 2018 127

Table 76: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2014 – 2018 131

Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2018–Q4 2018 132

Table 78: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2018 136

Table 79: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2018 137

List of Figures

1.2 List of Figures

Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2014- 2018 13

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2018-Q4 2018 15

Figure 3: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), 2018 17

Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2018 18

Figure 5: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2014 – 2018 25

Figure 6: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 26

Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2018 28

Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2014 – 2018 29

Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 30

Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2014 – 2018 31

Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2014 – 2018 32

Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2014 – 2018 34

Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2018 35

Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2014 – 2018 37

Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 38

Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2014 – 2018 39

Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2014 – 2018 40

Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2018 42

Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2014 – 2018 43

Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 44

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2018 45

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2018 46

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2018 47

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2018 48

Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2018 49

Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2018 50

Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2018 51

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2014 – 2018 54

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 55

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2018 56

Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2018 57

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2018 58

Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, 2018 59

Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2018 60

Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2018 61

Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2014 – 2018 64

Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 65

Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2018 66

Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2014 – 2018 68

Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 69

Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2018 70

Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2018 71

Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2018 72

Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2018 73

Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2014 – 2018 76

Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 77

Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2018, 2014 – 2018 81

Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 82

Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2014 – 2018 88

Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2018-Q4 2018 89

Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2014 – 2018 93

Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 94

Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2014 – 2018 98

Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 99

Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2014 – 2018 105

Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 106

Figure 57: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2014 – 2018 110

Figure 58: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018-Q4 2018 111

Figure 59: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2014 – 2018 115

Figure 60: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2018–Q4 2018 116

Figure 61: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2014 – 2018 120

Figure 62: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2018–Q4 2018 121

Figure 63: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2014 – 2018 125

Figure 64: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2018–Q4 2018 126

Figure 65: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2014 – 2018 130

Figure 66: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2018–Q4 2018 131

Figure 67: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2018 135

Figure 68: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2018 137

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports